Lilly and Merck pair 'breakthrough' therapies in latest cancer collaboration

Eli Lilly ($LLY) and Merck ($MRK) are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. Lilly is planning to sponsor a Phase I study combining its abemaciclib, a late-stage CDK 4/6 inhibitor, with Merck's Keytruda, which blocks the protein PD-1 to marshal an immune attack on tumor cells. The idea is to see whether the two drugs in tandem can make a difference in a variety of cancer types, and Lilly plans to embark on a Phase II effort if early signs are positive. Abemaciclib, which received the FDA's breakthrough therapy designation in October, is in late-stage development as a treatment for breast and lung cancers. Merck's therapy, another breakthrough designee, is approved in melanoma and lung cancer. Release

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.